Posted by Michael Wonder on 21 Nov 2022
TLV subsidises drugs against cystic fibrosis
18 November 2022 - The Dental and Pharmaceutical Benefits Agency, TLV, has decided that the drugs Kaftrio, Kalydeco and Symkevi, which treat cystic fibrosis, will be included in the high-cost protection.
It is gratifying that patients with cystic fibrosis, who have a great need for new treatments, now receive the medicines subsidized, says Jonathan Lind Martinsson, head of unit at TLV.
